Full-Time
Confirmed live in the last 24 hours
Develops robotic solutions for BPH treatment
Junior
Remote in UK
You match the following PROCEPT BioRobotics's candidate preferences
Employers are more likely to interview you if you match these preferences:
PROCEPT BioRobotics develops robotic solutions specifically for treating benign prostatic hyperplasia (BPH), a condition that affects many older men by causing prostate enlargement and urinary issues. Their main product, the AquaBeam Robotic System, utilizes Aquablation therapy, which combines real-time imaging, robotics, and waterjet technology to precisely remove prostate tissue in a minimally invasive manner. This system is designed for urologists and healthcare facilities, and the company generates revenue through the sale of the AquaBeam system and its disposable components, as well as offering training and support services. PROCEPT BioRobotics stands out from competitors by providing a solution that ensures predictable outcomes and minimizes complications, ultimately enhancing patient quality of life. The company's goal is to improve surgical procedures and patient outcomes in the treatment of BPH.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$319.1M
Headquarters
Redwood City, California
Founded
2009
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Parental Leave
Paid Holidays
Wellness Program
Gym Membership
What You Should Know:– The Mount Sinai Hospital has achieved a significant milestone in men’s health by performing New York City’s first procedures using the HYDROS™ Robotic System.– The technology offers a minimally invasive treatment option for benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.Impact of BPHBPH is a prevalent condition affecting millions of men, particularly those over 60. While non-cancerous, BPH can significantly impact quality of life, causing urinary symptoms such as frequent urination, weak stream, and nighttime urgency.Minimally Invasive Procedure Offers Hope for Men with BPHThe HYDROS™ system represents a major advancement in BPH treatment, building upon traditional methods like transurethral resection of the prostate (TURP) and laser treatments. It offers several key innovations:AI-Powered Treatment Planning: The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy.The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy. Advanced Visualization: HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning.HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning. Robotic-Assisted Waterjet Resection: The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction.The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction. Streamlined Workflow: HYDROS™ features an integrated tower for efficient setup, an adjustable touchscreen for improved ergonomics, and user-friendly software to guide surgeons through the procedure.Early Success and Expanding AccessMount Sinai urologists have successfully performed the health system’s first three HYDROS™ procedures, with all patients responding well and being discharged the following day
Robotics investments topped $7.4 billion for the month of October 2024, the result of 77 funding rounds. The investment total was led by Waymo’s $5.6 billion raise, which is the largest single round of the year through November. October’s total was the largest through the first 10 months of the year. The previous monthly high was the $3.7 billion raised in September 2024. The total investment for the period of January through October 2024 was more than $20 billion. Developers of autonomous driving technologies once again dominated the list of largest investments for the month
Procept BioRobotics announce a $175 million public stock offering, along with successful Q3 earnings.
PROCEPT BioRobotics operates in the medical sector and competes with medical robot and device makers like Intuitive Surgical, Medtronic PLC NYSE: MDT, and Zimmer Biomet Holdings NYSE: ZBH.
SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) at both academic and commercial settings. The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas. “The data presented at AUA confirm the safety and long-term durability of Aquablation therapy in treating men with symptomatic benign prostatic hyperplasia, regardless of prostate size or shape," said Reza Zadno, CEO of PROCEPT BioRobotics. “The fact that 12 abstracts were presented this past weekend underscores the growing body of real-world evidence to support that Aquablation therapy delivers the highest standard in urological care.” Icahn School of Medicine at Mount Sinai – 4-Year OutcomesAquablation therapy was performed on 275 adult men with moderate to severe BPH with a prostate volume between 38 and 293 mL (mean volume of 108.3 mL). The patients were out to 4 years post-procedure. Key results: Mean prostate volume decreased from 108.3 mL to 66.2 mL (-38.9%).International Prostate Symptom Score (IPSS) improved from 24.2 at baseline to 7.1 at 4 years.Peak urinary flow rate (Qmax) increased nearly 3-fold from 6.1 mL/sec to 17.1 mL/sec.Antegrade ejaculation was preserved for 99% of men.Surgical retreatment occurred in 1.8% patients